Skip to main content
padlock icon - secure page this page is secure

Cognition-Enhancing Drugs in Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD): An Update [1]

Buy Article:

$63.00 + tax (Refund Policy)

Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and agerelated pathologies such as MCI and AD. Development of cognition enhancers is still a difficult task because of the complexity of the brain functions, poor predictivity of animal tests and lengthy and expensive clinical trials. Current research is based on several working hypotheses, derived from the progress of knowledge in the neuro-bio-pathology of cognitive processes.

Approaches followed to develop cognition enhancing drugs, the results obtained in the past few years (since 2000) and the most promising molecules under study are reviewed.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: AMPA receptor; Aniracetam; NMDA receptor antagonist; NSAIDs; Neuromodulation; acetylcholinesterase (AChE) inhibitors

Document Type: Review Article

Affiliations: Dipartimento di Scienze Farmaceutiche, Universita' di Firenze, Polo Scientifico, Via U. Schiff, 6, 50019 Firenze, Italy.

Publication date: 01 December 2005

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more